Comparison of Antithrombotic, Anticoagulant, and Plasma aPC Concentration Following Infusion with Preactivated aPC, and Zymogens FLIN-Q3 and wt HPC
| Molecule Infused . | Infusion Rate (mg/kg/h) for Equivalent* . | ||
|---|---|---|---|
| . | Thrombus Weight† . | aPTT Ratio‡ . | Plasma aPC Concentrationρ . |
| aPC | 2.7 (1) | 1.6 (1) | 2.5 (1) |
| FLIN-Q3 | 24 (9) | 13 (8) | 19 (8) |
| HPC | 252 (93) | 220 (138) | 238 (95) |
| Molecule Infused . | Infusion Rate (mg/kg/h) for Equivalent* . | ||
|---|---|---|---|
| . | Thrombus Weight† . | aPTT Ratio‡ . | Plasma aPC Concentrationρ . |
| aPC | 2.7 (1) | 1.6 (1) | 2.5 (1) |
| FLIN-Q3 | 24 (9) | 13 (8) | 19 (8) |
| HPC | 252 (93) | 220 (138) | 238 (95) |
PC variants were infused for 15 minutes before and throughout a 15-minute period of blood circulation through the shunt. Blood was sampled after 30 minutes of infusion. All of the infusion doses were calculated from the best fit equation for a given dose response relationship. The correlation coefficient for dose and mean effect for each parameter was significant at P < .05. The numbers in parentheses represent the multiple relative to the value for aPC.
Approximate dose required to reduce thrombus weight by 50% of control. The aPTT ratio represents the experimental aPTT normalized to the pre-infusion control value.
Approximate dose required to prolong blood aPTT ratio 1.5× control.
ρ Approximate dose required to achieve a plasma concentration of 5 μg/mL determined using an immunocapture amidolytic assay.